Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction
- 31 May 2018
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 26 (12) , 4115-4120
Abstract
Purpose Patients with cancer often experience pain that affects their daily activities and quality of life. The analgesic ladder recommended by the World Health Organization has proved insufficient for many, and its scientific basis has been questioned. This retrospective study investigated factors related to adherence to long-term opioid therapy for patients with moderate cancer pain, including an evaluation of low-dose morphine relative to tramadol. Methods Clinical data were collected of patients with moderate cancer pain (n = 353) who received either low-dose morphine or tramadol and were followed for ≥ 27 weeks. Factors related to regime adherence were investigated, including the analgesia type, cancer therapy (antitumor therapy or palliative care), pain type (nociceptive, neuropathic, or mixed), and living distance to the hospital. Factors related to clinically meaningful pain reduction (≥ 30% reduction in pain from baseline) were also investigated. Results Patients taking tramadol, receiving antitumor therapy, experiencing neuropathic pain, and living far from the hospital were more likely to change analgesic strategy compared with, respectively, patients receiving low-dose morphine, palliative care, experiencing nociceptive pain, and living nearby. Factors that increased the likelihood of adherence to the analgesic regime were also associated with the likelihood of clinically meaningful pain reduction. Among adverse effects, a significantly higher percentage of patients experienced constipation in the tramadol group compared with those given morphine. Conclusions Among patients with moderate cancer pain, long-term low-dose morphine was safe and more effective than tramadol for clinically meaningful pain reduction, and patients were less likely to change the analgesic strategy.Keywords
Funding Information
- This work was funded by Science & Technology Department of Sichuan Province (2012SZ0143)
This publication has 22 references indexed in Scilit:
- Initial development and psychometric testing of an instrument to measure the quality of children’s end-of-life careBMC Palliative Care, 2015
- Serum concentrations of opioids when comparing two switching strategies to methadone for cancer painEuropean Journal of Clinical Pharmacology, 2012
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Validation of a needs‐based biopsychosocial distress instrument for cancer patientsPsycho-Oncology, 2011
- Prevalence of undertreatment in cancer pain. A review of published literatureAnnals of Oncology, 2008
- The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?Supportive Care in Cancer, 2006
- World Health Organization guidelines for cancer pain: a reappraisalAnnals of Oncology, 2005
- A validation study of the WHO analgesic ladder: a two-step vs three-step strategySupportive Care in Cancer, 2005
- Use of strong opioids in advanced cancer pain: a randomized trialJournal of Pain and Symptom Management, 2004
- Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer painPain, 1998